Enterprise 503B Solutions for Critical Drug Shortages
Ready-to-administer sterile IV bags and syringes with validated stability up to 60 days. Addressing the nationwide shortage affecting 142+ hospital systems with immediate deployment capabilities.
Cisplatin, carboplatin, and 15+ chemotherapy agents compounded in USP <800> negative-pressure isolators. Supporting cancer centers nationwide with consistent supply chains.
Custom concentrations and preservative-free options with weight-based dosing precision. Supporting children's hospitals with critical formulations unavailable commercially.
Full USP 797/800 compliance within our FDA-registered 503B facility. Audit-ready digital batch records with complete traceability and quality assurance protocols.
Emergency response line with nationwide cold-chain delivery infrastructure. Real-time inventory API integration for seamless hospital system integration.
Investigational drug service and clinical trial support for academic medical centers. Custom formulation development for unique patient populations.
When the supply chain fails, we deliver.